Advancing Harvard Medical School research, Dyno Therapeutics has raised $100m to advance its gene therapies based on AAV.
Dyno Therapeutics, a US-based gene therapy spinout of Harvard University, completed a $100m series A round yesterday that included GV, a corporate venturing subsidiary of internet and technology group Alphabet.
Venture capital firm Andreessen Horowitz led the round, which also featured life sciences investment firm Casdin Capital and VC firms Obvious Ventures, Lux Capital, CRV and KdT Ventures as well as investment firm Polaris Partners.
Dyno’s CapsidMap platform optimises adeno-associated virus capsid vectors, applying artificial intelligence and machine learning to the development of gene therapies.
The funding will go to platform development and expanding Dyno’s vectors from liver, muscle, eye and central nervous system diseases to lung, heart and kidney disease.
The company’s technology is based on intellectual property from the laboratory of George Church, the Robert Winthrop professor of genetics at Harvard Medical School. It launched in 2018 with a $9m round co-led by Polaris…
